Clinical Trial Detail

NCT ID NCT04038359
Title A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma. (TEMPO)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Verastem, Inc.
Indications

marginal zone B-cell lymphoma

non-Hodgkin lymphoma

follicular lymphoma

CLL/SLL

Therapies

Duvelisib

Age Groups: adult senior

No variant requirements are available.